ALEBUND-B

9637
20.1002.43% ( -0.500 )
Delay Closed: Nov 16, 16:08:11

Overview

ALEBUND-B (9637)

Alebund Pharmaceuticals (Jiangsu) Limited operates as a biopharmaceutical company that develops therapies for kidney diseases and their complications in China a...

Open
20.600
High
20.880
Low
19.810
Prev. Close
20.600
Volume
449.80K
Turnover
9.06M
Avg Price
20.146
Bid/Ask Ratio
33.33%
Amplitude
5.19%
52wk High
46.820
Volume Ratio
2.22
Turnover Ratio
0.22%
52wk Low
14.360
HK Mkt Cap
4.16B
Market CapHKD
6.99B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-2.33
EPSDynamic
-1.08
EPSStatic
--
BVPS
4.66
P/B
4.31
HK Shares
206.96M
Dividend YieldTTM
--
DividendTTM
--
Shares
347.95M
Min lot size
100
Currency
HKD

ALEBUND-B Analyst Rating

View more

Forecast & Rating

Sep 23, 2026
Price forecast
HK$48.51141.33%
Forecast & RatingStrong buy
3analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 13

    Alebund Pharmaceuticals (9637.HK) closed at HK$20.60, down 2.9% from the prior HK$21.22, tracing a dip-and-recover shape: an early push to HK$21.20 gave way to a morning-session low of HK$19.39 at 10:35 BJ, before afternoon buying lifted the stock back to HK$20.80, with 602,800 shares traded for HK$12.2 million and a turnover rate of only 0.31%. Repeated next-day disclosure returns on share buybacks over recent sessions have not reversed the drift. Q2 2026 revenue reached HK$60.15 million, up 806.48% year on year, while the net loss of HK$93.88 million narrowed 17.93% yoy, net margin at -156.06% and EPS at -HK$0.3309; partner R1 also presented the Phase IIb trial design for AP306 in hyperphosphatemia. The stock is 55.22% lower year to date and 56% below its 52-week high of HK$46.82 set on its 29 June listing, above the MA20 of HK$17.78 but below the MA60 of HK$23.90, with PB at 4.42. Though the afternoon rebound from HK$19.39 to HK$20.80 points to some support at the low.

  2. Nov, 11

    Alebund Pharmaceuticals reversed an early dip to close at HK$21.00, up 5.00% from the prior HK$20.00 close, after touching HK$19.90 at 11:18 BJ and then grinding to an intraday high of HK$21.00 at 15:57; the afternoon session carried 368,700 of the 419,900 shares traded, with a run of next-day disclosure returns announcing share buybacks over the past week acting as the main driver. Q2 2026 revenue reached HK$60.15m, up 806.48% year on year, while the net loss narrowed 17.93% to HK$93.88m and EPS improved 34.18% to -HK$0.3309, though net margin stayed at -156.06%. The stock sits above its MA20 of HK$17.72 but far below MA60 of HK$24.33, down 54.35% year to date and 55.15% below its HK$46.82 listing-day high, yet 46.24% above the HK$14.36 low of 22 October, with PB at 4.51x. The company remains loss-making, and a 0.20% turnover rate suggests buyback and trading volumes are modest against a HK$7.31bn market value.

  3. Nov, 6

    ALEBUND-B (9637.HK) opened at HK$18.00, dipped to that level at 09:32 BJ, then climbed to an intraday HK$19.37 by 10:13 and settled at HK$19.18, up 3.84% from the prior close of HK$18.47 on HK$12.56 million turnover. The bid followed four straight sessions of repurchases, including 74,100 shares for HK$1.2485 million on Nov 4 under a HK$100 million H-share buyback programme, while partner R1 presented the global Phase IIb multi-regional trial design poster for AP306 at ASN Kidney Week. Q2 2026 revenue reached HK$60.15 million, up 806.48% year on year, with the net loss narrowing 17.93% to HK$93.88 million and net margin still at -156.06%. The price sits above its MA20 of HK$18.36 but below MA60 of HK$25.00, down 58.30% year to date and 59.03% below the 52-week high of HK$46.82. Though a 4.12x price-to-book and negative PE leave profitability unproven.

  4. Nov, 5

    Alebund-B reversed early weakness to close up 6.15% at HK$18.47, supported by its ongoing HK$100 million buyback and partner R1's poster of the AP306 global Phase IIb multi-regional trial design at ASN Kidney Week. The morning session slid from HK$17.80 to HK$17.42; the afternoon dipped to HK$17.36 at 13:12 BJ before rallying to HK$18.70 at 14:01 and settling at HK$18.47 on 1.03 million shares and HK$18.71 million turnover. Buybacks ran at 58,300 shares on Nov 2, 12,200 on Nov 3 and 74,100 on Nov 4, for HK$995,900, HK$200,200 and HK$1,248,500 respectively. Q2 2026 revenue reached HK$60.15 million, up 806.48% year on year, while the net loss narrowed 17.93% to HK$93.88 million and EPS improved 34.18%. The stock is still down 59.85% year to date and 60.55% below its 52-week high of HK$46.82, with the HK$18.47 close just under the MA20 of HK$18.745 and far below the MA60 of HK$25.28. Though a 3.97 price-to-book and negative PE indicate profitability has not yet turned positive.

  5. Nov, 4

    Alebund Pharmaceuticals-B rebounded from its morning trough and finished at the session high of HK$17.400, up 5.39% from HK$16.510, after sliding to HK$15.650 at 11:08 in the morning session and climbing through the afternoon to that 15:59 print. The move followed execution of the buyback: under a HK$100 million H-share repurchase plan, the company spent HK$995,900 on 58,300 shares on 2 November and HK$200,200 on 12,200 shares on 3 November, while partner R1 presented the global Phase IIb design for AP306 at ASN Kidney Week and AP308 received FDA clinical clearance. Q2 2026 revenue of HK$60.15 million grew 806% year on year and the net loss of HK$93.88 million narrowed 17.9%, though net margin stayed at -156%. The stock remains 62.8% below its 52-week high of HK$46.82 and down 62.2% year to date, trading under its MA20 of HK$19.25; while market value is about HK$6.06 billion and PE is -7.48, profit has not turned positive and the repurchase is still small relative to market cap.

News